Publications by authors named "Aishah Ali Harshan"
Introduction: Leishmaniasis is a neglected tropical infectious disease. The available limited therapeutic options for leishmaniasis are inadequate due to their poor pharmacokinetic profile, resistance, toxicity, high cost, and compliance problems. This warrants identification of new targets for the development of safer and effective anti- therapy.
View Article and Find Full Text PDFThe advancement in therapy has provided a dramatic improvement in the rate of recovery among cancer patients. However, this improved survival is also associated with enhanced risks for cardiovascular manifestations, including hypertension, arrhythmias, and heart failure. The cardiotoxicity induced by chemotherapy is a life-threatening consequence that restricts the use of several chemotherapy drugs in clinical practice.
View Article and Find Full Text PDFArticle Synopsis
- The COVID-19 pandemic has led to a push for new treatments, with molnupiravir currently in phase 3 clinical trials as a promising oral medication.
- Originally developed for influenza, molnupiravir shows efficacy against SARS-CoV-2 and is being collaborated on by Emory University, Ridgeback Biotherapeutics, and Merck.
- With a reported good safety profile and expected market availability in early 2022, molnupiravir is anticipated to fulfill the need for an effective and patient-friendly COVID-19 treatment.